UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials

PloS one, 2011-09, Vol.6 (9), p.e22871-e22871

2011

Volltextzugriff (PDF)

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Emerging infectious diseases, 2020-08, Vol.26 (8), p.1792-1800

2020

Volltextzugriff (PDF)

Decreased Sensitivity of Rapid Antigen Test Is Associated with a Lower Viral Load of Omicron than Delta SARS-CoV-2 Variant

Microbiology spectrum, 2022-10, Vol.10 (5), p.e0192222-e0192222

2022

Volltextzugriff (PDF)

Weighted log‐rank test to compare two survival functions in the presence of dependent censoring

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2022-11, Vol.21 (6), p.1281-1293

Flandre, Philippe

2022

Volltextzugriff (PDF)

Risk Factors of Chronic Kidney Disease in HIV-infected Patients

Clinical journal of the American Society of Nephrology, 2011-07, Vol.6 (7), p.1700-1707

2011

Volltextzugriff (PDF)

Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study

PloS one, 2017-12, Vol.12 (12), p.e0187517-e0187517

2017

Volltextzugriff (PDF)

SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test

Life (Basel, Switzerland), 2022-12, Vol.12 (12), p.2064

2022

Volltextzugriff (PDF)

Choice of effect measure in HIV randomized trials

AIDS (London), 2015-09, Vol.29 (15), p.2057-2060

Flandre, Philippe

2015

Volltextzugriff (PDF)

Note on the role of the placebo group in the short‐term and long‐term hazard ratio model

Statistics in medicine, 2020-09, Vol.39 (20), p.2685-2688

2020

Volltextzugriff (PDF)

Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials

Journal of clinical epidemiology, 2018-04, Vol.96, p.63-72

2018

Volltextzugriff (PDF)

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

PloS one, 2012-07, Vol.7 (7), p.e41390-e41390

2012

Volltextzugriff (PDF)

Some current issues in the design of HIV noninferiority trials

AIDS (London), 2014-08, Vol.28 (13), p.1921-1929

FLANDRE, Philippe

2014

Volltextzugriff (PDF)

Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

Antimicrobial Agents and Chemotherapy, 2009-07, Vol.53 (7), p.2934-2939

2009

Volltextzugriff (PDF)

Design of HIV noninferiority trials: where are we going?

AIDS (London), 2013-02, Vol.27 (4), p.653-657

FLANDRE, Philippe

2013

Volltextzugriff (PDF)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

PloS one, 2015-06, Vol.10 (6), p.e0127816-e0127816

2015

Volltextzugriff (PDF)

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity

PloS one, 2013-10, Vol.8 (10), p.e74078-e74078

2013

Volltextzugriff (PDF)

Weighted Kaplan‐Meier estimators motivating to estimate HIV‐1 RNA reduction censored by a limit of detection

Statistics in medicine, 2020-03, Vol.39 (7), p.968-983

2020

Volltextzugriff (PDF)

Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy

Antimicrobial Agents and Chemotherapy, 2010-11, Vol.54 (11), p.4910-4913

2010

Volltextzugriff (PDF)

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

Current HIV research, 2011-01, Vol.9 (1), p.31-39

2011

Volltextzugriff (PDF)

Accuracy of predictive ability measures for survival models

Statistics in medicine, 2017-09, Vol.36 (20), p.3171-3180

2017

Volltextzugriff (PDF)

The Short-Term and Long-Term Hazard Ratio Model: Parameterization Inconsistency

The American statistician, 2021-10, Vol.75 (4), p.376-382

2021

Volltextzugriff (PDF)

Accuracy of predictive ability measures for survival models: P. FLANDRE, R. DEUTSCH AND J. O'QUIGLEY

Statistics in medicine, 2017-09, Vol.36 (20), p.3171-3180

2017

Volltextzugriff (PDF)

Comparing Kaplan–Meier curves with delayed treatment effects: applications in immunotherapy trials

Journal of the Royal Statistical Society Series C: Applied Statistics, 2019-08, Vol.68 (4), p.915-939

2019

Volltextzugriff (PDF)

Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings

Journal of antimicrobial chemotherapy, 2023-06, Vol.78 (6), p.1415-1422

2023

Volltextzugriff (PDF)

The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial

Journal of acquired immune deficiency syndromes (1999), 2019-05, Vol.81 (1), p.44-51

2019

Volltextzugriff (PDF)

1 – 25 von 99

Suche als RSS-Feed

Aktive Filter

SpracheFranzösisch

ThemaHiv-1 - Genetics

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(97)
Mit Volltextzugriff
(88)

Publikationsform

Artikel
(98)
Buchkapitel
(1)

Sprache

Englisch
(99)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Decreased Sensitivity of Rapid Antigen Test Is Associated with a Lower Viral Load of Omicron than Delta SARS-CoV-2 Variant

Weighted log‐rank test to compare two survival functions in the presence of dependent censoring

Risk Factors of Chronic Kidney Disease in HIV-infected Patients

Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study

SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test

Choice of effect measure in HIV randomized trials

Note on the role of the placebo group in the short‐term and long‐term hazard ratio model

Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

Some current issues in the design of HIV noninferiority trials

Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

Design of HIV noninferiority trials: where are we going?

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity

Weighted Kaplan‐Meier estimators motivating to estimate HIV‐1 RNA reduction censored by a limit of detection

Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

Accuracy of predictive ability measures for survival models

The Short-Term and Long-Term Hazard Ratio Model: Parameterization Inconsistency

Accuracy of predictive ability measures for survival models: P. FLANDRE, R. DEUTSCH AND J. O'QUIGLEY

Comparing Kaplan–Meier curves with delayed treatment effects: applications in immunotherapy trials

Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings

The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial

Aktive Filter

Suchergebnisse filtern